Tiotropium Respimat increases the risk of mortality

Thorax

Volumn 68, Issue 1, 2013, Pages 5-7

  Jenkins, Christine R ^a   Beasley, Richard ^b  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EDITORIAL; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HUMAN; INHALER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING CESSATION; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME;

EID: 84871361991     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202482     Document Type: Editorial

References (19)

1. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285.
2. Anthonisen N, Connet JE, Enright PL. Manfreda J and the lung health study research group. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002;166:333-9. (Pubitemid 34864422)
3. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010;363:1097-99.
4. Singh S, Loke YN, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008;300:1439-50. (Erratum in JAMA 2009;301:1227-30).
5. Tashkin DP, Celli B, Senn S, et al. UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
6. Singh S, Loke YK, Enright P, et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2012. doi:10.1136/thoraxjnl-2011-201275
7. Anderson P. Use of Respimat® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006;1:251-9.
8. Singh S, Yoon KL, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease : a systematic review and meta-analysis of randomized controlled trials. BMJ 2011;342:d3215.
9. Cates CJ. Safety of tiotropium: indirect evidence suggests the respimat inhaler is riskier than the handihaler. BMJ 2011;342:d2970.
10. Disse B, Metzdorf N, Martin A, et al. Mortality associated with tiotropium mist inhaler? A critical appraisal of the authors' selection and use of previously communicated tiotropium respimat data. BMJ 2011;342:d3215.
11. Singh S, Loke YL, Enright P, et al. Mortality associated with tiotropium mist inhaler? A critical appraisal of the authors' selection and use of previously communicated tiotropium Respimat data. BMJ 2011;342:d3215.
12. Dong Y-H, Lin H-H, Shau W-Y, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. Thorax 2012. doi: 10.1136/thoraxjnl-2012-201926
13. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. http://www.cochrane-handbook.org/ (accessed Aug 2012).
14. MedSafe, Ministry of Health, Wellington, New Zealand. Tiotropium Handihaler Datasheet. http://www.medsafe.govt.nz/profs/datasheet/s/Spirivacap. pdf (accessed Aug 2012).
15. Pulmonary-Allergy Drugs Advisory Committee Meeting, US Food and Drug Administration. Clinical Briefing Document, November 19 2009. NDA # 21-395 SpirivaHandihaler. http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/pulmonary-allergydrugsadvisorycommittee/ ucm190463.pdf (accessed Aug 2012).
16. van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat® Soft Mist inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9.
17. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med 2010;104:228-36.
18. Verhamme K, Afonso A, Romio S, et al. Increased risk of mortality in COPD patients using tiotropium Respimat vs tiotropium Handihaler. European Respiratory Society Annual Scientific Meeting; September 2012. Abstract 196.
19. Ram FSF, Carvallho CR, White J. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int J COPD 2011;6:129-39.